Journal Mobile Options
Table of Contents
Vol. 84, No. 5, 2013
Issue release date: May 2013
Section title: Review
Oncology 2013;84:311-318
(DOI:10.1159/000348325)

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

Lau W.-Y. · Sangro B. · Chen P.-J. · Cheng S.-Q. · Chow P. · Lee R.-C. · Leung T. · Han K.-H. · Poon R.T.P.
aFaculty of Medicine, Chinese University of Hong Kong, Hong Kong, SAR, China; bLiver Unit, Clínica Universitaria de Navarra and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Pamplona, Spain; cHepatitis Research and Department of Internal Medicine, National Taiwan University and Hospital, Taipei, Taiwan, ROC; dEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China; eDepartment of General Surgery, Singapore General Hospital, and fOffice of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore, Singapore; gDepartment of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; hComprehensive Oncology Centre, Hong Kong Sanatorium and Hospital Hong Kong, Hong Kong, SAR, China; iDepartment of Internal Medicine, Yonsei Liver Cancer Special Clinic, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea; jDepartment of Surgery, The University of Hong Kong, Hong Kong, SAR, China

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

Received: 11/20/2012 11:09:53 AM
Accepted: 1/18/2013
Published online: 4/18/2013

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Background/Purpose: Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) have an extremely poor prognosis and relatively few treatment options. Method: During a consensus meeting, experts met to examine the published data for HCC treatment strategies in patients with PVTT. Results: Many treatment guidelines consider the presence of PVTT a contraindication to partial hepatectomy or liver transplantation. Transarterial chemoembolization (TACE) is associated with an increased risk of ischemic necrosis of liver and of treatment-related death in patients with PVTT, and is, therefore, limited to a select group of patients with good hepatic function and adequate collateral circulation around the occluded portal vein. Systemic sorafenib results in survival benefit in patients regardless of the presence of PVTT. However, side effects are common, and there are no effects on time-to-symptom progression or quality of life. Transarterial radioembolization (TARE) with yttrium-90 microspheres is emerging as a valuable strategy. A wider range of patients with PVTT are suitable for this procedure compared to TACE. TARE is as effective as TACE in HCC and has quality-of-life advantages. Conclusion: In patients with HCC with PVTT, medical evidence suggests that TARE is a good choice of treatment.


  

Author Contacts

Prof. Joseph W.-Y. Lau
Faculty of Medicine, Chinese University of Hong Kong
Prince of Wales Hospital
Shatin, New Territories, Hong Kong, SAR (China)
E-Mail josephlau@surgery.cuhk.edu.hk

  

Article Information

Received: November 20, 2012
Accepted after revision: January 18, 2013
Published online: April 18, 2013
Number of Print Pages : 8
Number of Figures : 0, Number of Tables : 3, Number of References : 51

  

Publication Details

Oncology (International Journal for Cancer Research and Treatment)

Vol. 84, No. 5, Year 2013 (Cover Date: May 2013)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

Received: 11/20/2012 11:09:53 AM
Accepted: 1/18/2013
Published online: 4/18/2013

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.